NAMSA has completed its acquisition of WuXi AppTec’s U.S.-based medical device testing operations.

The Toledo, Ohio-based contract research organization (CRO) announced the move as part of its ongoing expansion in the medtech testing, clinical, and regulatory consulting space.

The acquisition brings together two established names in medical device biological safety testing, a field that serves more than 4,000 manufacturers worldwide. Lisa Olson, NAMSA’s senior vice president of global laboratory services, emphasized the increased expertise and capacity the deal provides.
“Together, we now have unmatched scientific expertise in biocompatibility, microbiology, preclinical, and extractables and leachables testing," she said. "With the addition of WuXi AppTec medical device testing facilities in the U.S., we now have more scientists, more lab capacity and more expertise with a wider variety of medical devices than any other company."

NAMSA has been expanding its footprint beyond biological safety testing in recent years, acquiring six companies focused on preclinical and clinical research since 2021.

Brian Smith, the company's newly appointed CEO, described the acquisition as part of a broader effort to enhance NAMSA’s service offerings. “This acquisition is part of our larger strategy to broaden our service offering and solidify our position as the go-to resource for manufacturers bringing new lifesaving technologies to market while upholding the same high standards of client-focused service you have come to expect from NAMSA,” he said.

Founded in 1967, NAMSA provides testing, clinical, and regulatory services to medical device manufacturers, supporting product development and commercialization.

HTM Homepage